AGN has commenced screening for the subjects in its Phase I DMT human stoke study!
Conducted in the Netherlands, AGN expects to open enrolment shortly and dose the first subject of the study in December 2022
DMT is a known psychedelic compound that is part of the tryptamine family and the purpose of the study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an IV with prolonged infusion.
There will be 60 volunteers enrolled across the two parts of the study with both psychedelic experience and psychedelic nave patients.
Notably, the preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor, an important part of the brains recovery process after an injury like a stroke.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-screens-first-subject-120000046.html